The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).
作者： Nur Aizati Athirah Daud , Muhamad Ali Sk Abdul Kader , Baharudin Ibrahim , Dzul Azri Mohamed Noor , Abubakar Sha’aban
DOI: 10.3390/MOLECULES26071987
关键词: Antiplatelet drug 、 Personalized medicine 、 Polymorphism (computer science) 、 Internal medicine 、 Clopidogrel 、 Platelet activation 、 Medicine 、 CYP2C19 、 Prevalence 、 Allele
摘要: … attributable to various genetic and non-genetic factors. This … the possible effects of genetic polymorphism on CR among … of drug metabolism-related genetic polymorphism, especially …
mdpi.com
sci-hub.st 参考文章(138)
Philippe L L’Allier, Grégory Ducrocq, Nicolas Pranno, Stéphane Noble, Reda Ibrahim, Jean C Grégoire, Fabian Azzari, Anna Nozza, Colin Berry, Serge Doucet, Benoit Labarthe, Pierre Théroux, Jean-Claude Tardif, PREPAIR Study Investigators, Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens: Results From the PREPAIR Randomized Study Journal of the American College of Cardiology. ,vol. 51, pp. 1066- 1072 ,(2008) , 10.1016/J.JACC.2007.12.013
Iris Müller, Felicitas Besta, Christian Schulz, Steffen Massberg, Albert Schönig, Meinrad Gawaz, Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thrombosis and Haemostasis. ,vol. 89, pp. 783- 787 ,(2003) , 10.1055/S-0037-1613462
Malcolm Robinson, John Horn, Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. ,vol. 63, pp. 2739- 2754 ,(2003) , 10.2165/00003495-200363240-00004
Diana A. Gorog, Valentin Fuster, Platelet function tests in clinical cardiology: unfulfilled expectations. Journal of the American College of Cardiology. ,vol. 61, pp. 2115- 2129 ,(2013) , 10.1016/J.JACC.2012.11.080
Gilles Montalescot, Georges Sideris, Catherine Meuleman, Claire Bal-dit-Sollier, Nicolas Lellouche, Ph Gabriel Steg, Michel Slama, Olivier Milleron, Jean-Philippe Collet, Patrick Henry, Farzin Beygui, Ludovic Drouet, ALBION Trial Investigators, A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. Journal of the American College of Cardiology. ,vol. 48, pp. 931- 938 ,(2006) , 10.1016/J.JACC.2006.04.090
D. Anichavezhi, U. S. Chakradhara Rao, D. G. Shewade, R. Krishnamoorthy, C. Adithan, Distribution of CYP2C19*17 allele and genotypes in an Indian population Journal of Clinical Pharmacy and Therapeutics. ,vol. 37, pp. 313- 318 ,(2012) , 10.1111/J.1365-2710.2011.01294.X
David J. Schneider, Anti-platelet therapy: glycoprotein IIb-IIIa antagonists. British Journal of Clinical Pharmacology. ,vol. 72, pp. 672- 682 ,(2011) , 10.1111/J.1365-2125.2010.03879.X
Amala P. Chirumamilla, Akiko Maehara, Gary S. Mintz, Roxana Mehran, Sunil Kanwal, Giora Weisz, Ahmed Hassanin, Diaa Hakim, Ning Guo, Usman Baber, Robert Pyo, Jeffrey W. Moses, Martin Fahy, Jason C. Kovacic, George D. Dangas, High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. Jacc-cardiovascular Imaging. ,vol. 5, pp. 540- 549 ,(2012) , 10.1016/J.JCMG.2011.12.019
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine. ,vol. 345, pp. 494- 502 ,(2001) , 10.1056/NEJMOA010746
Wei C. Lau, David G.M. Carville, Eric R. Bates, Clinical Significance of the Atorvastatin–Clopidogrel Drug–Drug Interaction Circulation. ,vol. 110, ,(2004) , 10.1161/01.CIR.0000137956.92971.4A